Plus   Neg

AstraZeneca: Lynparza Shows Improved Progression-free Survival Vs Chemotherapy

AstraZeneca (AZN.L) said, in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations, Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival compared with those who received chemotherapy (capecitabine, vinorelbine or eribulin). Initial findings from this Phase III OLYMPIAD study indicate that the safety profile of Lynparza was consistent with previous studies.

OLYMPIAD is a randomised, multi-center Phase III trial assessing the efficacy and safety of Lynparza (300 mg twice daily) to 'physician's choice' chemotherapy in 302 patients with HER2-negative metastatic breast cancer with germline BRCA1 or BRCA2 mutations, which are predicted or suspected to be deleterious. The international study was conducted in 19 countries.

AstraZeneca said its Phase III OLYMPIAD trial was the first positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer. A full evaluation of the OLYMPIAD data is ongoing and the results will be submitted for presentation at a forthcoming medical meeting.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Starbucks wants to be more efficient but it is risking the fragile loyalty of its most devoted customers. The ubiquitous chain plans a major push to get coffee lovers to use its mobile app to place their orders, but regulars prefer to buy their lattes by waiting in the queue. According to reports,... Taco Bell, the Mexican fast-food chain owned by Yum Brands Inc. (YUM), Thursday said it will start selling tortilla chips in grocery and convenience stores starting May. The chips will be available in Fire and Mild sauce packet flavors and also in a Classic flavor. "This launch of our first line... Meredith Corp. said Wednesday that it has decided to explore the sale of its Time, Sports Illustrated, Fortune, and Money brands. In addition, the company will cut 1,000 jobs over the next ten months as part of its plan to realize cost synergies from its acquisition of Time Inc. Further, Meredith has notified about 200 employees that their positions have been eliminated.
comments powered by Disqus
Follow RTT